Developing novel TCR-based therapies to treat hematologic malignancies, solid tumors, and rare diseases.

Our proprietary TCXpress TCR Discovery platform enables robust and efficient pipeline development for a vast array of clinical targets.

See the power of TCXpress™, our proprietary high throughput and automated TCR discovery platform.


To rapidly screen, identify and validate TCR-based therapies for accelerated delivery to the clinic.



We foster an environment where mutual kindness and consideration for all company members is expected.
  • Treat all people with dignity
  • Demonstrate a humble, open and positive attitude toward colleagues


We prize creativity and original ideas in all aspects of our work.
  • Be willing to think differently
  • Share thoughts and ideas openly
  • Embrace change


We know the success of the entire company relies on promoting coordination and cooperation between colleagues and teams.
  • Foster an openness for coordination across groups and teams
  • Recognize and embrace constructive feedback
  • Reward teamwork and contributions as well as leadership

Executional Excellence

We focus our efforts with a sense of urgency on the goals, objectives, and milestones that will advance TCXPress™ and NeoXPress™ to treat patients suffering from cancer.
  • Employ integrity and professionalism
  • Adhere to high quality standards and reward the development of expertise
  • Focus daily efforts on our critical path objectives



Keir Loiacono
Chief Executive Officer
Erkut Bahceci, MD
Chief Medical Officer
Bob Keefe
Chief Development Officer
Dr. Zhimei Du
Chief Scientific Officer
Kim Jaffe
Senior Vice President, Head of Business Development & Strategy
Tim Mayall
Vice President of Translational Development
Christopher Caracciolo
Vice President of Finance

Board of Directors

Board Member (UPMC Enterprises)
Chief Executive Officer
Board Member (Vir Pharma)
Co-Founder and Senior Advisor
Board Member (UPMC Enterprises)

Scientific Advisory Board

Co-Founder and Scientific Advisory Board Chairman
Director of the Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania
Edward Mallinckrodt Jr. Professor of Immunopathology, Microbiology and Immunobiology at Harvard Medical School
Associate Professor of Immunology at the University of Pittsburgh
Regents and Distinguished McKnight University Professor in the Department of Microbiology and Immunology Director of the Center for Immunology at the University of Minnesota
Ephraim P. Engleman Distinguished Professor Investigator, HHMI UCSF
Andrew M. and Jane M. Bursky Distinguished Professor  Department of Pathology and Immunology
Director, Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs

Take a look at current openings and be a part of our vision in giving every patient with cancer the opportunity for a cure.